On December 14, 2022, Titan Pharmaceuticals, Inc. hired Mr. David E. Lazar to serve as the Company's Chief Executive Officer, effective August 16, 2022. Prior to being named Chief Executive Officer of the Company, Mr. Lazar, age 32, has served as the Chief Executive Officer of Custodian Ventures LLC, a company which specializes in assisting distressed public companies through custodianship, since February 2018, and Activist Investing LLC, an actively managed investment fund, since March 2018. Mr. Lazar served as Managing Partner at Zenith Partners International Inc., a boutique consulting firm, from July 2012 to April 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.09 USD | +1.72% | -3.14% | -14.06% |
Apr. 01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
1st Jan change | Capi. | |
---|---|---|
-14.06% | 6.48M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- TTNP Stock
- News Titan Pharmaceuticals, Inc.
- Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022